TB-500 (Thymosin Beta-4) — Recovery Stack Companion to BPC-157

TB-500 is a synthetic version of Thymosin Beta-4, the most abundant peptide in human platelets and the dominant peptide in wound healing. Frequently paired with BPC-157 in recovery protocols. NexLife's peptide therapy program covers TB-500 under physician oversight.

The peptide

TB-500 is a synthetic version of Thymosin Beta-4, the most abundant peptide in human platelets and the dominant peptide in wound healing. The full Thymosin Beta-4 protein has 43 amino acids; TB-500 is the active fragment.

Mechanism

Upregulates actin polymerization. Promotes cell migration to sites of injury. Supports angiogenesis. Modulates inflammation. The combined effect is a substantially-shortened tissue-repair timeline in preclinical models.

BPC-157 + TB-500 — the recovery stack

The two are commonly stacked because their mechanisms complement: BPC-157 supports tendon/ligament/gut healing; TB-500 supports broader wound healing and immune modulation. Together they cover a wider biological footprint than either alone.

Dosing

Most common compounded protocol: 2–5 mg per week, subcutaneous, divided into 1–2 doses. Loading phase (4–6 weeks at higher dose) followed by maintenance phase (lower dose, 2× monthly).

Regulatory status

Approved in some countries for veterinary use; no FDA approval for human use. Compounded availability in the U.S. varies by state pharmacy board.

NexLife use

NexLife's peptide therapy program at $119/mo covers TB-500 under physician oversight by Medical Director Adam Kennah, M.D..

Sources

• Goldstein AL et al., Thymosin Beta-4 — Nature Rev Drug Discov
• Crockford D et al., Thymosin Beta-4 in wound healing — Ann NY Acad Sci
• Wei C et al., TB-500 in muscle repair — Int J Mol Med